Oculis Holding AG (OCS) Liabilities and Shareholders Equity (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Liabilities and Shareholders Equity of $311.6 million in Q1 2026, up 5.54% quarter-over-quarter from $295.2 million in Q4 2025, and up 37.21% on a YoY basis from $227.1 million in Q1 2025.
Oculis Holding AG (OCS) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Oculis Holding AG's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $311.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 37.21% year-over-year to $311.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 56.29% YoY), while the FY2025 annual figure was $295.2 million, up 114.89% from the prior year.
- Liabilities and Shareholders Equity was $311.6 million for Q1 2026 at Oculis Holding AG, up from $295.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $311.6 million in Q1 2026 to a low of $38.5 million in Q4 2022.
- Historically, Liabilities and Shareholders Equity has averaged $175.0 million across 5 years, with a median of $150.0 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity sank 38.89% in 2022, then jumped 235.12% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $38.5 million in 2022, then surged by 235.12% to $128.9 million in 2023, then increased by 6.57% to $137.4 million in 2024, then surged by 114.89% to $295.2 million in 2025, then climbed by 5.54% to $311.6 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $311.6 million (Q1 2026), $295.2 million (Q4 2025), and $209.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 640.56 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 311.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 311.58 Mn |
| Dec 31, 2025 | 295.23 Mn |
| Sep 30, 2025 | 209.81 Mn |
| Jun 30, 2025 | 219.38 Mn |
| Mar 31, 2025 | 227.09 Mn |
| Dec 31, 2024 | 137.39 Mn |
| Sep 30, 2024 | 144.98 Mn |
| Jun 30, 2024 | 153.41 Mn |
| Mar 31, 2024 | 113.09 Mn |
| Dec 31, 2023 | 128.92 Mn |
| Sep 30, 2023 | 145.98 Mn |
| Jun 30, 2023 | 149.97 Mn |
| Dec 31, 2022 | 38.47 Mn |
| Dec 31, 2021 | 62.95 Mn |